News
Pfizer Inc. boosts its oncology pipeline with strategic control of PD-1/VEGF bispecific drugs via 3SBio deal. Click for more on the deal and its PFE implications.
Hosted on MSN1mon
Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment DealBernstein analysts reaffirmed their Market Perform rating and $30 price target for Pfizer Inc. (NYSE:PFE) on May 20, following the company's recently disclosed $6 billion licensing deal with 3SBio ...
Image source: Getty Images. Entering a promising market. On May. 19, Pfizer announced it was entering into a licensing agreement with 3SBio, a China-based biotech company.Per the terms of the deal ...
Pfizer expands oncology pipeline with licensing deal worth up to $6 billion Pfizer secures exclusive global rights (excluding China) to SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, through ...
Pfizer made a splashy entrance late Monday, revealing it is paying $1.25 billion upfront and committing up to $4.8 billion in milestones for ex-China rights to 3SBio’s SSGJ-707. Pfizer is ...
In May, Pfizer inked an exclusive licensing deal with China's 3SBio for the latter’s dual PD-1 and VEGF inhibitor, which will strengthen its oncology pipeline.
Pfizer makes a $6 billion run into a new cancer drug race, 6 months after rival Pfizer’s licensing deal with China’s 3Sbio for PD-1/VEGF antibody has an upfront payment more than double what ...
Pfizer (PFE 0.30%) made a ... Pfizer announced it was entering into a licensing agreement with 3SBio, ... particularly thanks to its $43 billion acquisition of the smaller cancer specialist Seagen.
Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results